Background: Acute phosphate nephropathy (APN) is an underrecognized cause of acute kidney injury (AKI), typically associated with the use of oral sodium phosphate (OSP)-based bowel preparations. It is characterized by calcium phosphate crystal deposition within the renal tubules and may result in permanent renal impairment. Despite known risks, phosphate-containing solutions are still widely used without sufficient risk stratification. Methods: We retrospectively evaluated 517 native kidney biopsies performed in our nephrology clinic between 2017 and 2022. Among these, 12 patients with unexplained AKI and recent colonoscopy history were identified. In nine cases, non-specific tubular deposits on routine staining prompted further histochemical analysis. All had a history of recent OSP-based bowel cleansing. The use of von Kossa staining confirmed calcium phosphate deposition, consistent with APN. Results: Out of 517 kidney biopsies performed during the study period, 9 patients were diagnosed with APN based on histopathological findings following recent colonoscopy and OSP-based bowel cleansing. The mean age was 58.7 years, and three were female. Hypertension was present in seven patients, diabetes mellitus in three, and epilepsy in two; one patient had no comorbidities. Baseline renal function was normal (mean serum creatinine 0.86 mg/dL) and increased to 1.76 mg/dL at three months post-exposure. All biopsies revealed tubulointerstitial calcium phosphate deposits and interstitial inflammation; mesangial hypercellularity was observed in five cases, tubular atrophy in three, and acute tubular necrosis in one. All samples stained positive with von Kossa staining. Over time, all patients developed chronic kidney disease, and one progressed to end-stage renal disease requiring dialysis. Conclusions: In patients presenting with unexplained AKI and recent OSP-based bowel preparation, APN should be considered in the differential diagnosis. When routine histology is inconclusive, definitive diagnosis may require special histochemical staining. Risk-based restrictions on phosphate-containing agents are warranted to reduce preventable kidney injury.
14 May 2016 in Nephrology Dialysis Transplantation
Introduction and Aims: Severity of vascular calcifiacation is in close relation with the pathology of chronic dialysis premorbid conditions. In this cross-section study we aimed to see the factors influencing the severity of vascular calcifications in continuous ambulatory peritoneal dialysis (CAPD) patients population.
Objective: Rheumatoid arthritis (RA) is a systemic autoimmune disorder marked by chronic inflammation, with considerable heterogeneity in both disease trajectory and therapeutic response. The objective of this study is to assess whether RF and anti-CCP antibodies can serve as predictive markers for treatment outcomes in patients with rheumatoid arthritis undergoing anti-TNF-α therapy. Methods: This retrospective study analyzed 80 RA patients undergoing anti-TNF-α therapy (adalimumab, infliximab, or etanercept), stratified by serologic status: RF-positive alone (n = 27), anti-CCP-positive alone (n = 27), and double-seronegative (n = 26). Comprehensive disease activity assessment was performed using DAS28 scores, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) levels at baseline and following 12 months of treatment. Results: All groups showed significant improvement in ESR, CRP, and DAS28 scores after 12 months (p=0.001). No significant differences were observed between the groups in treatment response (p=0.587 for ESR, p=0.767 for CRP, p=0.999 for DAS28). Conclusion: RF and anti-CCP positivity did not significantly influence treatment response to anti-TNF therapy. Further studies with larger cohorts and quantitative antibody measurements are needed to confirm these findings.